Exelixis, Inc. (NASDAQ:EXEL)’s Latest Stock Updates


Dallas, Texas 04/24/2014 (FINANCIALSTRENDS) –  Exelixis, Inc. (NASDAQ:EXEL) is used to inhibit one of the leading proteins which drive tumour growth. The drug will now inhibit MET as well as VEGFR2 besides RET. These are some of the noted tumours which are useful in vascularization as well as metastasis growth.

Exelixis, Inc. (NASDAQ:EXEL) also has a portfolio which builds compounds. The drug used in treatment is focused on treating metastatic castration resistant prostate cancer or CRPC. The drug this biotechnology company provides is essential for medullary thyroid cancer as well as for the evaluation of other types of turmor.

Exelixis, Inc. (NASDAQ:EXEL) has a market capital of $671.66 million. The shares of this stock trade on the stock market at priced ranging between $3.60 and $3.39. The 52 week price range for this stock is between high of $8.41 and low of $3.02.

Exelixis, Inc. (NASDAQ:EXEL)previously opened on the stock market at prices of $3.59 per share. The EPS is negative for this stock and reads 1.33. The outstanding shares for this stock are 194.68 million. Beta is 2.28.

Exelixis, Inc. (NASDAQ:EXEL) is a South Francisco based biotechnology company which is engaged in developing therapies which will treat cancer. The therapy the company has developed relates to the use of small molecules and is used in treating cancer. The focus for the company has been on the development of resources for the drug – Cabozantinib or XL184.

Exelixis, Inc.(NASDAQ:EXEL)is in competition with such other drug makers as Roche Holding ltd as well as Sanofi SA. The rest include Bristol-Myers as well as Merck and co.  Along the line of services include the GlaxoSmithKline as well as other such as Pfizer as well as ArQule inc. Johnson and Johnson too are in the line-up of biotechnology companies which offer much competition to the likes of EXEL.